Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)

Hanny Al-Samkari, Wilma Barcellini, Nichola Cooper, Waleed Ghanima, Marc Michel, Raymond SM Wong, Francesco Zaja, Fengkui Zhang, Patrick Urban, Alex Allepuz, Justyna Fronczek-Sokol, Jens Haenig, Pascal Edrich, Adam Cuker

Blood (2023) 142 (Supplement 1): 5456.

https://doi.org/10.1182/blood-2023-180647

Published: 2023

Journal Articles

VAYHIT3: An Open-Label, Single-Arm, Phase II Trial to Evaluate the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (ITP) Previously Treated with at Least 1 Corticosteroid and 1 Thrombopoietin Receptor Agonist (TPO-RA)

David J Kuter, Charlotte A. Bradbury, Alex Allepuz, Nadège Pfender, Jens Haenig, Claus Nowak, Tomas Jose Gonzalez-Lopez

Blood (2023) 142 (Supplement 1): 5455.

https://doi.org/10.1182/blood-2023-180005

Published: 2023

Journal Articles

Efficacy and Safety of Eltrombopag Combined with Cyclosporine As First-Line Therapy in Adults with Severe Acquired Aplastic Anemia: Results of the Interventional Phase 2 Single-Arm Soar Study

Carlos Vallejo, Jun Ho Jang, Carlo Finelli, Efreen Montaño Figueroa, Lalita Norasetthada, Rodrigo T. Calado, Mehmet Turgut, Regis Peffault De Latour, Ulrike Kriemler-Krahn, Jens Haenig, Joan Maier, Phillip Scheinberg

Blood (2021) 138 (Supplement 1): 2174.

https://doi.org/10.1182/blood-2021-147733

Published: 2021

Journal Articles

ITP World Impact Survey (I-WISh) 2.0: Further Exploration of the Impact of ITP on Patients

Waleed Ghanima, Drew Provan, Nichola Cooper, MD, Axel Matzdorff, MDPhD, Ming Hou, Cristina Santoro, Mervyn Morgan, Caroline Kruse, Francesco Zaja, Leron Lahav, Yoshiaki Tomiyama, Michal Winograd, Barbara Lovrencic, Tom Bailey, MSci, Jens Haenig, James B. Bussel

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136651

Published: 2020

Journal Articles

A Phase II Study to Assess the Sustained Response Off Treatment in Patients with ITP Receiving Eltrombopag, Who Had a Previous Insufficient Response to Corticosteroids (TAPER): A Recruitment Update

Nichola Cooper, MD, Waleed Ghanima, Jens Haenig, James Lee, Masiur Rahman, Francesco Zaja

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137398

Published: 2020

Journal Articles

Physicians' and Patients' Perspectives on Treatments in ITP - a Multi-Country Perspective: Results from the ITP World Impact Survey (I-WISh)

James B. Bussel, MD, Waleed Ghanima, MD PhD, Yoshiaki Tomiyama, MD, Donald M. Arnold, MD, Drew Provan, MD, Ming Hou, MD PhD, Cristina Santoro, MD PhD, Serge Laborde, Alexandra Kruse, Caroline Kruse, Mervyn Morgan, Barbara Lovrencic, John Waller, PhD, Jens Haenig, Nichola Cooper, MD MRCP

Blood (2019) 134 (Supplement_1): 1097.

https://doi.org/10.1182/blood-2019-130591

Published: 2019

Journal Articles

Chronic Myeloid Leukemia Patients' Voice: Preliminary Results from the Italian Substudy of Enestpath (CAMN107AIC05), Exploring the Emotional Experience of Patients in the Context of Treatment-Free Remission

Lidia Borghi, PhD, Fausto Castagnetti, MD PhD, Franca Falzetti, MD, Massimiliano Bonifacio, MD, Enrico Capochiani, Francesca Lunghi, MD, Francesco Cavazzini, MD, Sara Galimberti, PhD MD, Claudia Minotto, Ester Maria Orlandi, MD, Simona Sica, MD, Claudia Galimberti, Jens Haenig, Sharon Supekar, Michele Baccarani, MD, Elena Vegni

Blood (2017) 130 (Supplement 1): 5654.

https://doi.org/10.1182/blood.V130.Suppl_1.5654.5654

Published: 2017

Journal Articles

ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase

Delphine Rea, MD PhD, Gianantonio Rosti, MD, Nicholas CP Cross, MA, PhD, Andrzej Hellmann, MD PhD, Dietger Niederwieser, MD, Ester Pungolino, MD, Franca Falzetti, MD, Patrizia Pregno, MD, Ester Maria Orlandi, MD, Antonio Almeida, MD PhD, Arpad Illes, MD PhD, Miguel Sagues, MD, Jens Haenig, PhD, Sharon Supekar, MSc, Seema Shah, MSc, Giuseppe Saglio, MD, Juan Luis Steegmann, MD, Michele Baccarani, MD

Blood (2016) 128 (22): 3094.

https://doi.org/10.1182/blood.V128.22.3094.3094

Published: 2016

Journal Articles

Reduced Expression of CD62L Is Associated with Increased ADAM17 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP)

Sieghart Sopper, PhD, Satu Mustjoki, MD PhD, Angelica Loskog, PhD, Bjorn T. Gjertsen, MD PhD, Ute Mark, Jens Haenig, Nidas Jurjonas, Gunther Gastl, Prof., Dr., Frank Giles, MDMB, Andreas Hochhaus, MD, Gert J Ossenkoppele, MD PhD, Kimmo Porkka, MD PhD, Dominik Wolf, MD

Blood (2014) 124 (21): 4522.

https://doi.org/10.1182/blood.V124.21.4522.4522

Published: 2014

Journal Articles

Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib

Blood (2013) 122 (21): 2731.

https://doi.org/10.1182/blood.V122.21.2731.2731

Published: 2013

Journal Articles

Early PK-Analysis Predicts Molecular Response In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib

Blood (2013) 122 (21): 1485.

https://doi.org/10.1182/blood.V122.21.1485.1485

Published: 2013

NARROW

A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)

VAYHIT3: An Open-Label, Single-Arm, Phase II Trial to Evaluate the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (ITP) Previously Treated with at Least 1 Corticosteroid and 1 Thrombopoietin Receptor Agonist (TPO-RA)

Efficacy and Safety of Eltrombopag Combined with Cyclosporine As First-Line Therapy in Adults with Severe Acquired Aplastic Anemia: Results of the Interventional Phase 2 Single-Arm Soar Study

ITP World Impact Survey (I-WISh) 2.0: Further Exploration of the Impact of ITP on Patients

A Phase II Study to Assess the Sustained Response Off Treatment in Patients with ITP Receiving Eltrombopag, Who Had a Previous Insufficient Response to Corticosteroids (TAPER): A Recruitment Update

Physicians' and Patients' Perspectives on Treatments in ITP - a Multi-Country Perspective: Results from the ITP World Impact Survey (I-WISh)

Chronic Myeloid Leukemia Patients' Voice: Preliminary Results from the Italian Substudy of Enestpath (CAMN107AIC05), Exploring the Emotional Experience of Patients in the Context of Treatment-Free Remission

ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase

Reduced Expression of CD62L Is Associated with Increased ADAM17 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP)

Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib

Early PK-Analysis Predicts Molecular Response In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only